Tech startup OrganOx, a spinoff from the University of Oxford, has been bought out for a staggering $1.5 billion.

In a significant move for the global medtech industry, Terumo Corporation has announced the acquisition of OrganOx, a University of Oxford spin-off specialising in liver perfusion technology. The deal, worth $1.5 billion, marks one of the largest exits of a UK medtech company and a major milestone for OrganOx, which developed the world's first fully automated device for liver preservation, the metra.

Over the years, OrganOx has made a significant impact on patient outcomes, with the metra technology being used in over 6,000 liver transplants. This innovative technology has not only increased the number of viable organs available for transplant but has also improved patient outcomes.

Business Growth Fund (BGF), one of the largest and most experienced growth capital investors in the UK and Ireland, has been a key player in OrganOx's success. BGF first invested in OrganOx in 2019 and has provided seven rounds of investment, including a 20m GBP commitment this year. BGF is now the company's largest shareholder and participated in each of the funding rounds following its initial investment.

The success of the OrganOx exit is tied directly to its positive impact on patient outcomes. This success is a testament to BGF's strategy of supporting high-potential UK medtech companies, as demonstrated by its investments in Cyted, TidalSense, and Entia.

Cyted, another BGF-backed company, uses AI-enabled diagnostics for early cancer detection, while TidalSense develops innovative respiratory monitoring technology. Entia, on the other hand, is a home blood testing platform supporting cancer care.

The business will continue to operate from Oxford as a standalone division within Terumo Corporation after the completion of the transaction. This move is expected to expand OrganOx's transplantation technology platform through Terumo's global infrastructure, benefiting more patients worldwide.

This deal follows BGF's recent exit from Panthera Biopartners, a leading clinical trials site management organization, and the Development Bank of Wales supporting a medtech business with a £500k investment.

In a broader context, BGF recently pledged 500m GBP to early-stage deep tech and life sciences businesses as part of its wider 3bn GBP UK-wide strategy to support high-potential companies over the next five years. This commitment underscores BGF's dedication to fostering innovation and growth in the UK's medtech sector.

Meanwhile, Neurovalens, a Northern Irish medtech company, has secured £6m investment in a round led by the Investment Fund for Northern Ireland. This investment will support Neurovalens' mission to revolutionise the treatment of neurological disorders.

As the medtech sector continues to evolve, investments like these are crucial in driving innovation, improving patient outcomes, and making a significant impact on global health.

Tech startup OrganOx, a spinoff from the University of Oxford, has been bought out for a staggering $1.5 billion.